Fig. 6: Pilot scale multiplex orthoflavivirus screen.

Performance of reference compounds as shown in (a–c) as quality control during the screen. Antiviral activity of the five reference compounds, namely 7DMA, BDAA, JNJ-A07, ST-148 and NITD008, was assessed through a series of independent repeat experiments (n = 5). a The best antiviral activity for each individual reference compound per experiment were plotted on the RGB cube (Supplementary Movie 3) and b deconvoluted on series of RGB palettes and white-black scale for visualization of specificity and potency. c Dose response curves for reference compounds. The data presented as means ± SD (n = 5) from independent experiments. d Raw data of all n = 1256 compounds subjected to the multiplex screen (plotted as in b). e Selection of hits (n = 49) with sufficient activity (>70% activity against at least one virus). Compounds with unspecific high cytotoxicity (>30% reduction cell count) were excluded. f Hit profile with n = 37 candidate showing activity to only one virus, n = 11 dual-activity and n = 1 pan-Orthoflavivirus activity. Source data are provided as a Source Data file, including overlapping data points not readily visible on the graphs.